4.6 Article

Efficacy of sarolaner-(Simparica®) against induced infestations of Haemaphysalis longicornis on dogs

期刊

PARASITES & VECTORS
卷 12, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s13071-019-3765-4

关键词

Haemaphysalis longicornis; Efficacy; Isoxazoline; Oral; Sarolaner; Simparica (R); Dog; Tick

资金

  1. Zoetis Japan KK

向作者/读者索取更多资源

Background: Haemaphysalis longicornis is the major tick affecting dogs in most of the East Asia/Pacific region and has recently been detected in a number of areas of the USA. This tick is a vector for a number of pathogens of dogs, other mammals and humans. In this study, the efficacy of a single oral administration of sarolaner (Simparica (R), Zoetis) at the minimum label dosage (2 mg/kg) was evaluated against an existing infestation of H. longicornis and subsequent weekly reinfestations for 5 weeks after treatment. Methods: Sixteen dogs were ranked on pretreatment tick counts and randomly allocated to treatment on Day 0 with sarolaner at 2 mg/kg or a placebo. The dogs were infested with H. longicornis nymphs on Days - 2, 5, 12, 19, 26 and 33. Efficacy was determined at 48 hours after treatment and subsequent re-infestations based on live tick counts relative to placebo-treated dogs. Results: There were no adverse reactions to treatment. A single dose of sarolaner provided 100% efficacy on Days 2, 7, 14 and 21; and >= 97.4% efficacy on Days 28 and 35. Considering only attached, live ticks, efficacy was 100% for the entire 35 days of the study. Geometric mean live tick counts for sarolaner were significantly lower than those for placebo on all days (11.62 <= t((df)) <= 59.99, where 13.0 <= df <= 14.1, P < 0.0001). Conclusions: In this study, a single oral administration of sarolaner at 2 mg/kg provided 100% efficacy against an existing infestation of H. longicornis nymphs and >= 97.4% efficacy (100% against attached ticks) against weekly reinfestation for at least 35 days after treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据